Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohort
Open Access
- 6 March 2023
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (10) , 4507-4519
Abstract
Introduction: Plasma biomarkers—cost effective, non‐invasive indicators of Alzheimer's disease (AD) and related disorders (ADRD)—have largely been studied in clinical research settings. Here, we examined plasma biomarker profiles and their associated factors in a population‐based cohort to determine whether they could identify an at‐risk group, independently of brain and cerebrospinal fluid biomarkers.Methods: We measured plasma phosphorylated tau181 (p‐tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and amyloid beta (Aβ)42/40 ratio in 847 participants from a population‐based cohort in southwestern Pennsylvania.Results: K‐medoids clustering identified two distinct plasma Aβ42/40 modes, further categorizable into three biomarker profile groups: normal, uncertain, and abnormal. In different groups, plasma p‐tau181, NfL, and GFAP were inversely correlated with Aβ42/40, Clinical Dementia Rating, and memory composite score, with the strongest associations in the abnormal group.Discussion: Abnormal plasma Aβ42/40 ratio identified older adult groups with lower memory scores, higher dementia risks, and higher ADRD biomarker levels, with potential implications for population screening.Highlights: Population‐based plasma biomarker studies are lacking, particularly in cohorts without cerebrospinal fluid or neuroimaging data. In the Monongahela‐Youghiogheny Healthy Aging Team study (n = 847), plasma biomarkers associated with worse memory and Clinical Dementia Rating (CDR), apolipoprotein E ε4, and greater age. Plasma amyloid beta (Aβ)42/40 ratio levels allowed clustering participants into abnormal, uncertain, and normal groups. Plasma Aβ42/40 correlated differently with neurofilament light chain, glial fibrillary acidic protein, phosphorylated tau181, memory composite, and CDR in each group. Plasma biomarkers can enable relatively affordable and non‐invasive community screening for evidence of Alzheimer's disease and related disorders pathophysiology.Keywords
Funding Information
- National Institutes of Health (R37 AG023651)
- Alzheimer's Association (AARFD‐22‐923814, AARFD‐22‐974627, AACSF‐20‐648075, #AARF‐21‐850325)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.336490/2019‐00)
- National Institute on Aging (R01 AG023651, R01AG075336, R01AG073267)
- Vetenskapsrådet (#2018‐02532, Vetenskapsrådet #2021‐03244)
- Hjärnfonden (#FO2022‐0270)
- UK Dementia Research Institute (UKDRI‐1003)
This publication has 52 references indexed in Scilit:
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersThe Lancet Neurology, 2013
- Astrocytes: Conductors of the Alzheimer disease neuroinflammatory symphonyExperimental Neurology, 2013
- GeneralizabilityNeurology, 2012
- Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer DementiaArchives of General Psychiatry, 2012
- Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brainNeurobiology of Aging, 2010
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004
- Age and education correction of Mini-Mental State Examination for English- and Spanish-speaking elderlyNeurology, 1996
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Partitioning Around Medoids (Program PAM)1990
- “Mini-mental state”Journal of Psychiatric Research, 1975